

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex:

Unknown

Specimen Collected: 14-Sep-23 12:40

Phosphatidylethanol (PEth), Whole Blood | Received: 14-Sep-23 12:40

Report/Verified: 14-Sep-23 12:42

| Procedure | Result | Units | Reference Interval |
|-------------------------|------------------------|-------|--------------------|
| PEth 16:0/18:1 (POPEth) | 42 ⁱ¹ | ng/mL | |
| PEth 16:0/18:2 (PLPEth) | 37 ⁱ² | ng/mL | |
| EER_Phosphatidylethanol | EERUnavailable | | |
| PEth Interpretation | See Note ⁱ³ | | |

Test Information

i1: PEth 16:0/18:1 (POPEth)
 PEth 16:0/18:1 (POPEth)
 Less than 10 ng/mL.....Not detected
 Less than 20 ng/mL.....Abstinence or light alcohol consumption
 20 - 200 ng/mL.....Moderate alcohol consumption
 Greater than 200 ng/mL.....Heavy alcohol consumption or chronic alcohol use

(Reference: W. Ulwelling and K Smith 2018 J. Forensic Sci)

i2: PEth 16:0/18:2 (PLPEth)
 Reference ranges are not well established.

i3: PEth Interpretation
 Phosphatidylethanol (PEth) is a group of phospholipids formed in the presence of ethanol, phospholipase D and phosphatidylcholine. PEth is known to be a direct alcohol biomarker. The predominant PEth homologues are PEth 16:0/18:1 (POPEth) and PEth 16:0/18:2 (PLPEth), which account for 37-46% and 26-28% of the total PEth homologues, respectively. PEth is incorporated into the phospholipid membrane of red blood cells and has a general half-life of 4-10 days and a window of detection of 2-4 weeks. However, the window of detection is longer in individuals who chronically or excessively consume alcohol. The limit of quantification is 10 ng/mL. Serial monitoring of PEth may be helpful in monitoring alcohol abstinence over time. PEth results should be interpreted in the context of the patient's clinical and behavioral history.
 Patients with advanced liver disease may have falsely elevated PEth concentrations (Nguyen VL et al 2018, Alcoholism Clinical & Experimental Research).

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-257-900144

Report Request ID: 18466430

Printed: 14-Sep-23 14:29